Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea

Urology

Volumn 75, Issue 5, 2010, Pages 1156-1161

  Chang, Hyuk Soo ^a   Park, Choal Hee ^a   Kim, Dae Kyung ^b   Park, Jong Kwan ^c   Hong, Sung Joon ^d   Chung, Byung Ha ^d   Lee, Jeong Gu ^e   Kim, Choung Soo ^f   Lee, Kyu Sung ^g   Kim, Joon Chul ^h  

^a Keimyung University School of Medicine   (South Korea)

^b Eulji University   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

TAMSULOSIN;

ADULT; ARTICLE; BOTHERSOMENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; KOREA; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT RESPONSE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM; REPUBLIC OF KOREA; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77951665401     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.010     Document Type: Article

References (22)

1. Weiss J.P., Blaivas J.G., Anger J.A.T., et al. Development and validation of a new treatment outcome score for men with lutes. Neurourol Urodyn. 23 (2004) 88-93
2. Rovner E.S., Kreder K., Sussman D.O., et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 180 (2008) 1034-1041
3. Biggs G.Y., Ballert K.N., Rosenblum N., et al. Patient-reported outcomes for tension-free vaginal tape-obturator in women treated with a previous anti-incontinence procedure. Int Urogynecol J Pelvic Floor Dysfunct. 20 (2009) 331-335
4. De E., Pisters L.L., Pettaway C.A., et al. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma, and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol. 177 (2007) 2200-2204
5. El-Azab A.S., Abd-Elsayed A.A., and Imam H.M. Patient reported and anatomical outcomes after surgery for pelvic organ prolapse. Neurourol Urodyn. 28 (2009) 219-224
6. Cappelleri J.C., and Stecher V.J. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective. Int J Impot Res. 20 (2008) 343-357
7. Andersson K.-E. Mode of action of α1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU Int. 85 (2000) 12-18
8. Schwin D.A. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 88 suppl 2 (2001) 27-34
9. Abrams P., Schulman C.C., and Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). Br J Urol. 76 (1995) 325-336
10. Chapple C.R., Wyndaele J.J., Nordling J., et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 29 (1996) 155-167
11. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51 (1998) 892-900
12. Park C.H., Chang H.S., Oh B.R., et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Clin Drug Invest. 24 (2004) 41-47
13. Li N.C., Chen S., Yang X.H., et al. Efficacy of low-dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Invest. 23 (2003) 781-787
14. Rahardjo D., Soebadi D.M., Sugandi S., et al. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 13 (2006) 1405-1409
15. Suzuki H., Yano M., Awa Y., et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand medical outcomes Study 36-item Health Survey. Int J Urol. 13 (2006) 1202-1206
16. Yalla S.V., Sullivan M.P., Lecamwasam H.S., et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol. 153 (1995) 674-679
17. McConnell J.D., Barry M.J., Bruskewitz R.C., et al. Benign prostatic hyperplasia: diagnosis and treatment, clinical practice guideline No. 8 (1994), Department of Health and Human Services, Agency for Health Care Policy and Research, Public Health Service, US, Rockville, MD Publication No. 94-0582
18. Groutz A., Blaivas J.G., Chaikin D.C., et al. Noninvasive outcome measures for urinary incontinence: a multicenter study of voiding diaries and pad tests. J Urol. 164 (2000) 698-701
19. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al., AUA Measurement Committee. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148 (1992) 1549-1557
20. Blaivas J.G., and Chancellor M. Deciding on the right urodynamic equipment. In: Blaivas J., and Chancellor M. (Eds). Atlas of Urodynamics (1997), Williams and Wilkins, Baltimore, MD 19-37
21. Michel M.C., Mehlburger L., Bressel H.-U., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1 (1998) 332-335
22. Barry M.J., Williford W.O., Chang Y., et al. Benign prostatic hyperplasia specific healthy status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol. 154 (1995) 1770-1774